vs
Atmos Energy（ATO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Atmos Energy的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Atmos Energy净利率更高（30.0% vs 12.7%，领先17.3%），Atmos Energy同比增速更快（14.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-725.3M），过去两年Revvity的营收复合增速更高（9.0% vs -9.7%）
Atmos Energy总部位于美国得克萨斯州达拉斯，是美国规模最大的纯天然气分销商之一，业务覆盖美国9个州的1400多个社区，为东起蓝岭山脉、西至落基山脉区域内的约300万天然气用户提供服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ATO vs RVTY — 直观对比
营收规模更大
ATO
是对方的1.7倍
$772.1M
营收增速更快
ATO
高出8.3%
5.9%
净利率更高
ATO
高出17.3%
12.7%
自由现金流更多
RVTY
多$887.1M
$-725.3M
两年增速更快
RVTY
近两年复合增速
-9.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $403.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 38.3% | 14.5% |
| 净利率 | 30.0% | 12.7% |
| 营收同比 | 14.2% | 5.9% |
| 净利润同比 | 14.5% | 3.9% |
| 每股收益（稀释后） | $2.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATORVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $737.5M | $698.9M | ||
| Q2 25 | $838.8M | $720.3M | ||
| Q1 25 | $2.0B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $657.9M | $684.0M | ||
| Q2 24 | $701.5M | $691.7M | ||
| Q1 24 | $1.6B | $649.9M |
净利润ATORVTY
| Q4 25 | $403.0M | $98.4M | ||
| Q3 25 | $174.9M | $46.7M | ||
| Q2 25 | $186.4M | $53.9M | ||
| Q1 25 | $485.6M | $42.2M | ||
| Q4 24 | $351.9M | $94.6M | ||
| Q3 24 | $134.0M | $94.4M | ||
| Q2 24 | $165.6M | $55.4M | ||
| Q1 24 | $432.0M | $26.0M |
毛利率ATORVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | 60.0% | 56.5% | ||
| Q4 24 | 80.1% | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | 62.1% | 54.6% |
营业利润率ATORVTY
| Q4 25 | 38.3% | 14.5% | ||
| Q3 25 | 29.8% | 11.7% | ||
| Q2 25 | 30.1% | 12.6% | ||
| Q1 25 | 32.2% | 10.9% | ||
| Q4 24 | 39.1% | 16.3% | ||
| Q3 24 | 28.1% | 14.3% | ||
| Q2 24 | 31.4% | 12.4% | ||
| Q1 24 | 33.4% | 6.8% |
净利率ATORVTY
| Q4 25 | 30.0% | 12.7% | ||
| Q3 25 | 23.7% | 6.7% | ||
| Q2 25 | 22.2% | 7.5% | ||
| Q1 25 | 24.9% | 6.4% | ||
| Q4 24 | 29.9% | 13.0% | ||
| Q3 24 | 20.4% | 13.8% | ||
| Q2 24 | 23.6% | 8.0% | ||
| Q1 24 | 26.2% | 4.0% |
每股收益（稀释后）ATORVTY
| Q4 25 | $2.44 | $0.86 | ||
| Q3 25 | $1.04 | $0.40 | ||
| Q2 25 | $1.16 | $0.46 | ||
| Q1 25 | $3.03 | $0.35 | ||
| Q4 24 | $2.23 | $0.77 | ||
| Q3 24 | $0.82 | $0.77 | ||
| Q2 24 | $1.08 | $0.45 | ||
| Q1 24 | $2.85 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $367.0M | $919.9M |
| 总债务越低越好 | $9.6B | — |
| 股东权益账面价值 | $14.3B | $7.3B |
| 总资产 | $29.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.67× | — |
8季度趋势，按日历期对齐
现金及短期投资ATORVTY
| Q4 25 | $367.0M | $919.9M | ||
| Q3 25 | $202.7M | $931.4M | ||
| Q2 25 | $709.4M | $991.8M | ||
| Q1 25 | $543.5M | $1.1B | ||
| Q4 24 | $584.5M | $1.2B | ||
| Q3 24 | $307.3M | $1.2B | ||
| Q2 24 | $674.6M | $2.0B | ||
| Q1 24 | $262.5M | $1.7B |
总债务ATORVTY
| Q4 25 | $9.6B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.9B | — | ||
| Q1 25 | $8.4B | — | ||
| Q4 24 | $8.4B | — | ||
| Q3 24 | $7.8B | — | ||
| Q2 24 | $7.8B | — | ||
| Q1 24 | $7.4B | — |
股东权益ATORVTY
| Q4 25 | $14.3B | $7.3B | ||
| Q3 25 | $13.6B | $7.4B | ||
| Q2 25 | $13.4B | $7.6B | ||
| Q1 25 | $13.1B | $7.6B | ||
| Q4 24 | $12.8B | $7.7B | ||
| Q3 24 | $12.2B | $7.9B | ||
| Q2 24 | $12.2B | $7.9B | ||
| Q1 24 | $11.6B | $7.8B |
总资产ATORVTY
| Q4 25 | $29.8B | $12.2B | ||
| Q3 25 | $28.2B | $12.1B | ||
| Q2 25 | $27.7B | $12.4B | ||
| Q1 25 | $27.0B | $12.4B | ||
| Q4 24 | $26.5B | $12.4B | ||
| Q3 24 | $25.2B | $12.8B | ||
| Q2 24 | $24.9B | $13.4B | ||
| Q1 24 | $24.0B | $13.4B |
负债/权益比ATORVTY
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.64× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.64× | — | ||
| Q1 24 | 0.64× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $308.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-725.3M | $161.8M |
| 自由现金流率自由现金流/营收 | -54.0% | 21.0% |
| 资本支出强度资本支出/营收 | 77.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.76× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-1.6B | $509.4M |
8季度趋势，按日历期对齐
经营现金流ATORVTY
| Q4 25 | $308.1M | $182.0M | ||
| Q3 25 | $348.1M | $138.5M | ||
| Q2 25 | $496.4M | $134.3M | ||
| Q1 25 | $922.9M | $128.2M | ||
| Q4 24 | $282.0M | $174.2M | ||
| Q3 24 | $330.7M | $147.9M | ||
| Q2 24 | $411.2M | $158.6M | ||
| Q1 24 | $746.6M | $147.6M |
自由现金流ATORVTY
| Q4 25 | $-725.3M | $161.8M | ||
| Q3 25 | $-615.5M | $120.0M | ||
| Q2 25 | $-370.6M | $115.5M | ||
| Q1 25 | $83.3M | $112.2M | ||
| Q4 24 | $-609.2M | $149.8M | ||
| Q3 24 | $-477.3M | $125.6M | ||
| Q2 24 | $-302.4M | $136.6M | ||
| Q1 24 | $100.7M | $129.7M |
自由现金流率ATORVTY
| Q4 25 | -54.0% | 21.0% | ||
| Q3 25 | -83.5% | 17.2% | ||
| Q2 25 | -44.2% | 16.0% | ||
| Q1 25 | 4.3% | 16.9% | ||
| Q4 24 | -51.8% | 20.5% | ||
| Q3 24 | -72.5% | 18.4% | ||
| Q2 24 | -43.1% | 19.7% | ||
| Q1 24 | 6.1% | 20.0% |
资本支出强度ATORVTY
| Q4 25 | 77.0% | 2.6% | ||
| Q3 25 | 130.7% | 2.6% | ||
| Q2 25 | 103.4% | 2.6% | ||
| Q1 25 | 43.0% | 2.4% | ||
| Q4 24 | 75.8% | 3.4% | ||
| Q3 24 | 122.8% | 3.3% | ||
| Q2 24 | 101.7% | 3.2% | ||
| Q1 24 | 39.2% | 2.7% |
现金转化率ATORVTY
| Q4 25 | 0.76× | 1.85× | ||
| Q3 25 | 1.99× | 2.97× | ||
| Q2 25 | 2.66× | 2.49× | ||
| Q1 25 | 1.90× | 3.03× | ||
| Q4 24 | 0.80× | 1.84× | ||
| Q3 24 | 2.47× | 1.57× | ||
| Q2 24 | 2.48× | 2.87× | ||
| Q1 24 | 1.73× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATO
| Distribution Segment | $1.3B | 94% |
| Transportation Revenue | $41.5M | 3% |
| Other | $39.4M | 3% |
| Miscellaneous Revenue | $2.8M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
